济宁侯氏{风湿}(烟台手指风湿关节炎怎样治) (今日更新中)

Hospitals and states collecting case data on COVID-19 patients will now be reporting that data directly to the federal government, instead of the CDC's online database.Beginning this week, according to an update on the Health and Human Services website, states and hospitals are being asked to submit data directly to the federal government and task force in an effort to cut down on duplicate requests and minimize the reporting burden on hospitals and facilities.“As of July 15,, 2020, hospitals should no longer report the Covid-19 information in this document to the National Healthcare Safety Network site,” the statement reads. The emphasis was added in the original document.The National Healthcare Safety Network site is the CDC’s site for tracking infectious diseases.The document says the change in reporting will help the White House coronavirus task force to allocate supplies like personal protective gear, ventilators and drugs like remdesivir.Some are worried the change in where the data will be kept means a change in public access to the data.“Historically, C.D.C. has been the place where public health data has been sent, and this raises questions about not just access for researchers but access for reporters, access for the public to try to better understand what is happening with the outbreak," Jen Kates, the director of global health and H.I.V. policy with the nonpartisan Kaiser Family Foundation, told the the New York Times, who first reported on this change.Many researchers, scientific modelers and health officials in municipalities around the country rely on the CDC’s data to make projections and time-sensitive decisions.Michael Caputo, the assistant secretary for public affairs at the department, said in a statement to CNN, a "new faster and complete data system is what our nation needs to defeat the coronavirus and the CDC, an operating division of HHS, will certainly participate in this streamlined all-of-government response. They will simply no longer control it."The document shared by Health and Human Services does not clarify how the data will be accessed by the public. 2128

Halloween may be a little spookier this year. A blue moon is set to light up the sky on Oct. 31.Many have heard the phrase, “once in a blue moon.” It refers to something rare, just like this celestial event. NASA says we’re only treated to blue moons every two and a half years, on average.A blue moon is the second full moon in a calendar month, according to modern folklore. And since there are 29 days between moons and most months have 30 or 31 days, having two full moons in a month doesn’t happen often.The next blue moon isn’t expected until Aug 31, 2023, according to MoonGiant.com.Don’t expect a giant blue orb in the sky though. These moons look the same as any other.Before the blue moon on Halloween, another full moon will appeared in the sky on Oct. 1. The first was called the harvest moon and the second will be referred to as the hunter’s moon, according to the Old Farmer’s Almanac.The Farmer’s Almanac says a full moon on Halloween is also rare and only happens every 18 to 19 years. 1010

From right, actors Luigi Lo Cascio, Linda Caridi and Laura Morante with director Daniele Luchetti and actor Adriano Giannini pose during the photo call for the movie Lacci opening the 77th edition of the Venice Film Festival at the Venice Lido, Italy, Tuesday, Sept. 2, 2020. The Venice Film Festival will go from Sept. 2 through Sept. 12. Italy was among the countries hardest hit by the coronavirus pandemic, and the festival will serve as a celebration of its re-opening and a sign that the film world, largely on pause since March, is coming back as well. (AP Photo/Domenico Stinellis) 597

Guests will get to visit one of the world's most famous landmarks after it was closed due to COVID-19.The Eiffel Tower is set to reopen June 25, and guests 11 years or older will be required to wear masks.The tower had been closed since March.On its website, officials said in a statement that as a safety protocol, guests would only be allowed to use stairs for the first and second floors.Officials added that the elevators and the top floor of the tower would remain closed for the time being."As the situation evolves, the lifts taking our visitors to the second floor can be quickly put back into service under appropriate conditions, with a minimal number of people on-board," officials said in the statement. "The top-level remains closed for now since the lifts taking visitors from second to the top floor are small. It might re-open during the summer."A re-opening date for the online ticket office has not been made available. 945

Holidays will look different this year for many Americans, with dinners outside, social distancing, or passing on family gatherings altogether. But several companies developing rapid at-home COVID-19 tests are hopeful that won't be the case next year. The goal is to make inexpensive, easy-to-use COVID tests that can deliver results in minutes, just like a pregnancy test. "For people to feel comfortable to associate with friends or family, there needs to be a testing methodology ideally that can be performed at home," said Tony Lemmo, CEO of the manufacturing company BioDot.The company's technology is being used by over 70 manufacturers worldwide making COVID-19 antigen, antibody, and PCR tests. Their automated platforms dispense nanoliter/picoliter amounts of reagent onto the tests accurately and fast.Lemmo says just one of their systems can support the production of roughly 100 million COVID-19 tests per year, helping to make high-volume production possible.“We knew we were going to be called on by customers to manufacture more equipment to provide them the ability to manufacture more tests," said Lemmo. To meet customer demand, BioDot increased staffing and built a new facility, compressing production time from months to weeks. The FDA recently authorized the first rapid at-home test that can deliver results in 30 minutes, eliminating the need for a lab to test the sample. But the molecular single-use test will only be available to patients with a doctor's prescription who are suspected of being infected with COVID-19.Companies developing tests hope the FDA will soon authorize another at-home testing tool: the rapid antigen test.These inexpensive tests provide results within minutes, and companies developing them say millions could be sold without a doctor's referral.“From what we’re hearing, it’s really just a matter of possibly months before there’s at least sufficient data to be able to support an at-home use of a test like an antigen test," said Lemmo.Lemmo says if authorized by the FDA, manufacturers could make millions of these tests in a matter of months. But antigen tests are less accurate, and the FDA wants to ensure they'll be simple enough for people to use at home. There are also concerns over how the data will be reported to health authorities. “I think any at-home testing or massive rollout of a test into the communities needs to be done very carefully and with a lot of education around it," said Clinical Lab Director Melissa Miller. Dr. Miller is a professor of pathology and laboratory medicine at the University of North Carolina Chapel Hill and Medical Director for the Clinical Microbiology Lab for the Medical Center.She worries the inaccuracies of these tests could eventually lead the public to lose trust in all testing. “Even at 98 percent specificity, which is very, very high. That means you’re going to have a false positive two out of every 100. If you started testing a hundred million people, this is millions of people who have a false-positive test," said Dr. Miller. She says this could lead to healthy people isolating and missing work or school unnecessarily, and false-negative results could give people a false sense of security. “These rapid antigen tests were pushed out to skilled nursing facilities; this is a very high-risk patient population. This is actually where you want a very accurate test," said Dr. Miller. She says it’s unclear how well antigen tests detect the virus in asymptomatic patients but agrees more data is needed to figure that out.“It might make more sense for K-12 schools, or even college settings, where there’s less risk for a poor outcome if you have a false positive or a false negative," said Dr. Miller. But with a growing demand for convenient at-home testing, manufacturers are hopeful that in the months ahead, the FDA will soon open the door to new solutions. 3889

来源：资阳报